Given the critical role of dosage in the balance between infection and organ rejection, further trials and broader immunologic monitoring are necessary to obtain a deeper understanding of the potential benefits of an anti-CD40 and anti-CD40L co-stimulation blockade in preclinical cardiac xenotransplantation. This evidence concerns the gene CD40 and infection.